Get the Stockscreener App
1.38
0.00%
0.00
After Hours:
1.39
0.01
+0.72%
Okyo Pharma Limited stock is traded at $1.38, with a volume of 87,733.
It is up +0.00% in the last 24 hours and down -11.54% over the past month.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
See More
Previous Close:
$1.38
Open:
$1.36
24h Volume:
87,733
Relative Volume:
0.83
Market Cap:
$72.42M
Revenue:
-
Net Income/Loss:
$-4.61M
P/E Ratio:
-11.00
EPS:
-0.1254
Net Cash Flow:
$-3.10M
1W Performance:
+1.47%
1M Performance:
-11.54%
6M Performance:
-12.66%
1Y Performance:
-37.84%
1-Day Range:
$1.32
$1.40
1-Week Range:
$1.2862
$1.41
52-Week Range:
$1.28
$3.20
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.38 | 72.42M | 0 | -4.61M | -3.10M | -0.1254 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Piper Sandler | Overweight |
| Dec-08-25 | Initiated | B. Riley Securities | Buy |
Okyo Pharma Limited Stock (OKYO) Latest News
OKYO Pharma Ltd Share PriceOKYO, RNS News, Articles, Quotes, & Charts (NASDAQ:OKYO) - Proactive financial news
OKYO Pharma (NASDAQ: OKYO) to Host Fireside Chat at Cantor Global Healthcare Conference on September 10, 2026 - Kalkine Media
OKYO Pharma to Showcase Urcosimod at Key European Ophthalmology Forums - TipRanks
111-patient eye pain trial planned by OKYO Pharma (NASDAQ: OKYO) - Stock Titan
OKYO Pharma (OKYO) to Showcase Advances at Ophthalmology Futures Forum and ESCRS iNovation Day Amid Phase 3 NEPTUNE Trial Progress - Kalkine Media
A late-stage trial is planned to test a one-dose treatment for corneal nerve pain - Stock Titan
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026 - manilatimes.net
OKYO Pharma Ltd ADR (NASDAQ: OKYO) Share Price, OKYO Stock News, OKYO Share Price & Updates - Kalkine
OKYO Pharma (NASDAQ: OKYO) readies Phase 3 trial of eye-pain drug urcosimod - Stock Titan
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference - marketscreener.com
OKYO Pharma to participate in Cantor Global Healthcare Conference - Proactive financial news
Piper Sandler Maintains OKYO Pharma(OKYO.US) With Buy Rating, Maintains Target Price $7 - Moomoo
OKYO (OKYO) Trading: Ends Higher by 2.67% at $1.54 in the Latest Reading; Traders Can Monitor the $1.46-$1.62 Range under the Current SnapshotFactor ETF Flow - dars.gov.et
OKYO (OKYO) Session: Posts a 2.67% Gain to $1.54 in Latest Trading; Chart Watch: Price Remains Between $1.46 Support and $1.62 Resistance in the Latest ReadingVolatility Surface - vinanet.vn
OKYO (OKYO) Watch: Declines 0.33% to $1.51 on the Day; Key Range: the Supplied Trading Band Runs From $1.43 to $1.59 for the Current SessionCounter Trend Trade - vinanet.vn
OKYO Pharma (OKYO) Edges Up 1.33% to $1.52 as Support at $1.44 HoldsCalendar Spread Trade - vinanet.vn
Short Interest in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Expands By 223.4% - MarketBeat
OKYO Pharma Ltd (OKYO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OKYO Pharma (NASDAQ: OKYO) updates 20-F to add clawback policy exhibit - stocktitan.net
OKYO Pharma (OKYO) director buys 5,000 shares in open market - Stock Titan
Price to sales forward of OKYO Pharma Limited – NASDAQ:OKYO - tradingview.com
OKYO Pharma (OKYO) Expected to Post Quarterly Earnings on Monday - MarketBeat
Form 4 OKYO Pharma Ltd For: 29 July By Investing.com - Investing.com Canada
OKYO Pharma CSO buys shares - Proactive financial news
OKYO Pharma CSO purchases additional shares at $1.49 By Investing.com - Investing.com Nigeria
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer - The Manila Times
OKYO Pharma (Nasdaq: OKYO) CSO boosts stake, plans Phase 3 NCP trial - Stock Titan
OKYO Pharma scientist's holdings reach 20,030 shares after purchase - Stock Titan
OKYO Pharma CSO Increases Stake Ahead of Planned Phase 3 Trial - TipRanks
OKYO Pharma to participate in BTIG Biotechnology Conference 2026 - Proactive financial news
OKYO Pharma Ltd (OKYO) Cash Flow - TradingKey
OKYO Pharma (NASDAQ:OKYO) Is In A Good Position To Deliver On Growth Plans - simplywall.st
OKYO Pharma to Participate in BTIG Biotechnology Conference 2026 - Quiver Quantitative
OKYO Pharma (Nasdaq: OKYO) plans Phase 3 NCP trial, joins BTIG conference - Stock Titan
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 - GlobeNewswire
OKYO Pharma Ltd (OKYO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OKYO Pharma Ltd (OKYO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OKYO Pharma Ltd (OKYO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OKYO Pharma Ltd (OKYO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OKYO Pharma Ltd (OKYO) Institutional Confidence - TradingKey
OKYO Pharma Ltd (OKYO) Valuation: PE, PB & Fair Value Analysis - TradingKey
OKYO Pharma Limited Revenue Breakdown – GETTEX:OK11 - TradingView
OKYO|OKYO Pharma Ltd|Price:1.530|Chg%:+0.020 - TradingKey
TradingKey - TradingKey
OKYO Pharma outlines path to phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain - Ophthalmology Times Europe
Form 4 OKYO Pharma Ltd For: 24 July By Investing.com - Investing.com South Africa
OKYO Pharma Declines Slightly, Tests Support Near $1.39 as Biotech Sector Faces PressureSmall Cap Breakouts - careplusvn.com
OKYO Pharma (OKYO) grants 3,500 shares to chief development officer - Stock Titan
OKYO Pharma CEO Robert Dempsey Acquires 15,000 Shares at $1.54 Ahead of Phase 3 Trial Launch - Kalkine Media
OKYO Pharma director buys 5,000 shares at $1.48, increasing his stake to 35,201 shares. - Pluang
OKYO Pharma Director John Brancaccio Purchases 5,000 Shares on Nasdaq - Quiver Quantitative
Okyo Pharma Limited Stock (OKYO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):